Type I Vasoactive Intestinal Polypeptide Receptors

A pituitary adenylate cyclase-activating polypeptide receptor subtype that binds both PACAP and VASOACTIVE INTESTINAL PEPTIDE. It is found predominately in the BRAIN.

Also Known As:

Receptors, Vasoactive Intestinal Polypeptide, Type I; PACAP Receptors, Type II; PACAP Type II Receptor; PACAPR-2 Protein; Receptor, VIP1; VIP 1 Receptor; VIP-1 Receptor; VIP1 Receptor; VIP1 Receptors; VIPR1 Protein; VPAC1 Receptor; Vasoactive Intestinal Peptide 1 Receptor; Vasoactive Intestinal Peptide Receptor 1; PACAPR 2 Protein; Pituitary Adenylate Cyclase Activating Peptide Receptor Type II; Receptor, VIP 1; Receptor, VIP-1; Receptor, VPAC1; Receptors, VIP1; Pituitary Adenylate Cyclase-Activating Peptide Receptor Type II; Receptors, Pituitary Adenylate Cyclase-Activating Peptide, Type II; VIP Receptors, Type I; Vasoactive Intestinal Peptide Receptors, Type I

Networked: 38 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Cell Surface Receptors: 2125
      - G-Protein-Coupled Receptors: 4701
        Pituitary Adenylate Cyclase-Activating Polypeptide Receptors: 106
        Vasoactive Intestinal Peptide Receptors: 216
        Type I Vasoactive Intestinal Polypeptide Receptors: 38
        human VIPR1 protein
        mouse Vipr1 protein
        rat Vipr1 protein

Experts

1.	Abad, Catalina: 2 articles (01/2017 - 01/2016)
2.	Becquet, Laurine: 2 articles (01/2017 - 01/2016)
3.	Jayaram, Bhavaani: 2 articles (01/2017 - 01/2016)
4.	O'Dorisio, M Sue: 2 articles (01/2017 - 01/2016)
5.	Tan, Yossan-Var: 2 articles (01/2017 - 01/2016)
6.	Wang, Yuqi: 2 articles (01/2017 - 01/2016)
7.	Waschek, James A: 2 articles (01/2017 - 01/2016)
8.	Thakur, Mathew L: 2 articles (01/2010 - 12/2007)
9.	Wickstrom, Eric: 2 articles (01/2010 - 12/2007)
10.	Zhang, Kaijun: 2 articles (01/2010 - 12/2007)

Related Diseases

1.	Migraine Disorders (Migraine) 01/01/2022 - "The localization of PACAP in a subpopulation of CGRP-expressing neurons in the trigeminal ganglion points toward a primary sensory function although a dendritic release cannot be excluded which could stimulate the VPAC1 receptor or the PAC1 and VPAC2 receptors on immune cells in the meninges, initiating neurogenic inflammation relevant for migraine pathology." 10/12/2023 - "Recent studies have revealed the presence of PACAP and its corresponding receptors, namely, the pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1R), vasoactive intestinal peptide receptor 1 (VIPR1), and vasoactive intestinal peptide receptor 2 (VIPR2), in various structures implicated in migraine pathophysiology, including sensory trigeminal neurons. "
2.	Type 2 Diabetes Mellitus (MODY) 02/01/2016 - "In a previous study, the single-nucleotide polymorphism (SNP) rs9677, mapped in the 3'-UTR of vasoactive intestinal peptide receptor 1 (VPAC1) gene, was found to be associated with type 2 diabetes (T2D) in Caucasian women. " 02/10/2012 - "Gender-dependent association of type 2 diabetes with the vasoactive intestinal peptide receptor 1."
3.	Neoplasms (Cancer) 01/01/2019 - "Vasoactive intestinal peptide receptor 1 (VIPR1) is observed to express differently in human malignancies. " 01/01/2010 - "The 2 benign tumors that did not express the VPAC1 receptor were not imaged. " 01/30/2004 - "Because VPAC1 receptor antagonists increase the survival and reduce the tumor burden in C3(1)SV40Tag mice, they may function as chemopreventive agents in mammary cancer." 01/01/2013 - "The VPAC1 receptor, a member of the vasoactive intestinal peptide receptors (VIPRs), is overexpressed in the most frequently occurring malignant tumors and plays a major role in the progression and angiogenesis of a number of malignancies. " 10/01/2011 - "Twenty-one percent of the tumor samples expressed only the VPAC1 receptor and 16% displayed only the VPAC2 receptor, while 13 samples (30%) expressed neither subtype. "
4.	Breast Neoplasms (Breast Cancer) 12/04/2007 - "RT-PCR confirmed increased VPAC1 receptor expression on human breast tumor cells over normal cells and corroborated with autoradiography data. " 12/11/1998 - "Therefore VIP1 receptors may be utilized for the early detection and treatment of breast cancer." 12/11/1998 - "VIP1 receptors are present in breast cancer cells. " 01/30/2004 - "Because VPAC1 receptor antagonists increase the survival and reduce the tumor burden in C3(1)SV40Tag mice, they may function as chemopreventive agents in mammary cancer." 01/02/2012 - "RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells."
5.	Infections 02/15/2002 - "We have discovered a cellular receptor, VPAC1, that is a novel and potent facilitator of HIV-1 infection and thus, is a potentially important new target for therapeutic intervention." 05/01/2011 - "Vasoactive intestinal peptide receptor 1 is downregulated during expansion of antigen-specific CD8 T cells following primary and secondary Listeria monocytogenes infections." 01/01/2020 - "Here, we show that Salmonella enterica serovar Typhimurium 4/74 significantly increased expression of mRNA of a type 1 receptor (VPAC1) for anti-inflammatory vasoactive intestinal peptide (VIP) in murine ileum and mesenteric lymph nodes at day 6 post-infection (d6 pi) and in the spleen at d3 pi. "

Related Drugs and Biologics

1.	Type II Vasoactive Intestinal Peptide Receptors
2.	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)
3.	Messenger RNA (mRNA)
4.	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))
5.	Vasoactive Intestinal Peptide Receptors (Vasoactive Intestinal Peptide Receptor)
6.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
7.	Cytokines
8.	Interleukin-6 (Interleukin 6)
9.	Peptides (Polypeptides)
10.	Oligonucleotides